Stealth BioTherapeutics Presents Data for Elamipretide on Cardiac Function in Barth Syndrome

Print Friendly, PDF & Email

BOSTON, Oct. 17, 2019 /PRNewswire/ — Stealth BioTherapeutics (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the presentation of new data from the open-label extension portion of the Phase 2/3 TAZPOWER study evaluating elamipretide […]